Quantum-Si (NASDAQ:QSI) Issues Quarterly Earnings Results

Quantum-Si (NASDAQ:QSI) posted its quarterly earnings data on Thursday. The company reported ($0.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.02, FiscalAI reports. The business had revenue of $0.21 million for the quarter, compared to analysts’ expectations of $0.27 million. Quantum-Si had a negative net margin of 6,138.26% and a negative return on equity of 47.12%.

Here are the key takeaways from Quantum-Si’s conference call:

• Quantum-Si said Proteus remains on track for a second-quarter 2027 launch. It reported that instrument design is complete, variability issues are substantially addressed, and manufacturing of the next development build is underway, with initial instruments expected this quarter.
• The company has demonstrated detection of 19 amino acids and expects to demonstrate the 20th by year-end, with all 20 targeted for launch. At World HUPO, interim Proteus results showed about 30 times more sequencing output per chamber than Platinum Pro and a lower false discovery rate, though management said the product is still in development.
• Quantum-Si has held Proteus Roadshow events in more than 35 cities and launched a pre-order program offering priority access and pricing. Management described prospective-customer interest as encouraging and said the sales funnel includes both existing users and new accounts, but did not disclose order numbers.
• Revenue fell to $212,000 from $552,000 year over year in the quarter, and the company reiterated full-year 2026 revenue guidance of about $1 million as customers await Proteus. Quantum-Si reported $149.4 million in cash, equivalents and marketable securities and said it expects funding to last into the fourth quarter of 2028.
• The company lowered its 2026 adjusted operating expense outlook to $87 million or less from $98 million or less and cash-use outlook to $87 million or less from $93 million or less, citing cost actions and discipline. It is also ordering long-lead components earlier amid AI-related supply constraints, which may increase near-term working capital needs; management said it does not currently expect the constraints to affect the launch timeline.

Quantum-Si Trading Up 13.7%

Quantum-Si stock opened at $1.33 on Friday. The stock has a market cap of $291.11 million, a P/E ratio of -3.41 and a beta of 3.26. The company has a fifty day simple moving average of $1.09 and a 200-day simple moving average of $0.97. Quantum-Si has a 12-month low of $0.69 and a 12-month high of $1.81.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Alliance Global Partners reiterated a “buy” rating on shares of Quantum-Si in a research report on Friday, August 14th. Wall Street Zen upgraded Quantum-Si from a “sell” rating to a “hold” rating in a research note on Tuesday, October 27th. HC Wainwright set a $4.00 price target on Quantum-Si in a report on Friday, October 9th. Finally, Weiss Ratings raised shares of Quantum-Si from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 24th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $2.50.

Quantum-Si Company Profile

Quantum-Si Incorporated (NASDAQ:QSI) is a life sciences technology company focused on transforming protein analysis through next-generation proteomics. The company develops tools designed to identify and characterize proteins at the single-molecule level, with potential applications in drug discovery, translational research, diagnostics development and precision medicine.

Its primary offering is the Platinum platform, which combines a benchtop sequencing instrument, semiconductor-based technology, consumables and data-analysis software.